ROCKVILLE, Md., April 4 /PRNewswire-FirstCall/ -- InforMedix Holdings, Inc. (BULLETIN BOARD: IFMX) today announced that it has received the Frost & Sullivan 2005 Technology Innovation & Leadership of the Year Award in Patient Monitoring for successfully developing and piloting a web-based medication-monitoring device called Med-eMonitor(TM) System. The Med-eMonitor System is an integrated hardware, software, and medication packaging system, which enables patients and their clinicians in remote locations to efficiently track and improve medication compliance on a continual basis.
“InforMedix was recognized for their innovative technology deployment with the Med-eMonitor(TM) device and its ability to truly evolve and set a precedent for the standard of care delivered to home health patients,” noted Frost & Sullivan, research analyst Vivek Subramany.
Through the Med-eMonitor(TM) System researchers, clinicians and pharmaceutical companies can easily collect, deliver, manage and monitor real-time patient medication compliance and protocol adherence data. The Med-eMonitor(TM) is a portable device connected to an Internet-accessible database. It functions as a drug dispenser and electronic patient diary in one.
In the report, Frost & Sullivan stated that the true innovative quality of Med-eMonitor(TM) is its ability to close the communication gap between patients and physicians through the transfer of information on a continuous basis, regardless of the patient and physician’s proximity, and enable higher quality outcomes. It is this consistently proactive approach to home healthcare that will continue to decrease medical error and acute admission rates in the near to long term and drive demand for innovative devices such as Med-eMonitor(TM).
Dr. Bruce Kehr, CEO of InforMedix stated, “We are honored to receive this award from Frost & Sullivan. We believe that it is imperative to ensure that medication and care are self-administered properly and monitored accurately and efficiently. Our goal is to play a critical role in improving patient drug safety by improving the communications between the physician and patient.”
InforMedix was recognized at the 2005 Excellence in Medical Devices & Healthcare Awards Banquet in San Francisco, CA on Wednesday, March 16.
ABOUT INFORMEDIX
InforMedix is a growing medical technology company with a proprietary device and software solution for enhancing medication compliance and safety monitoring of patients in clinical trials and disease management markets. Clinical studies have demonstrated the Company’s Med-eMonitor System(TM) to deliver 94% medication adherence and 96% protocol adherence in participating patient populations. InforMedix’ strategic alliances with McKesson BioServices and other leaders in the clinical trial and disease management markets are driving customer penetration. InforMedix’ 15 issued patents (plus 14 pending) have been cited as prior art in over 150 other issued patents. To find out more about InforMedix, Inc. (BULLETIN BOARD: IFMX) , visit our website at http://www.informedix.com/.
ABOUT FROST & SULLIVAN
Frost & Sullivan, a global growth consulting company founded in 1961, partners with clients to create value through innovative growth strategies. The foundation of this partnership approach is our Growth Partnership Services platform, whereby we provide industry research, marketing strategies, consulting, and training to our clients to help grow their business. A key benefit that Frost & Sullivan brings to its clients is a global perspective on a broad range of industries, markets, technologies, econometrics, and demographics. With a client list that includes Global 1000 companies, emerging companies, as well as the investment community, Frost & Sullivan has evolved into one of the premier growth consulting companies in the world. For more information, visit http://www.frost.com/.
This report contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. These statements include those stated in the Frost & Sullivan report as set forth in the fourth paragraph of this press release. References made to the discussion of the risk factors are detailed in the Company’s filings with the Securities and Exchange Commission, including the report on Form 10-QSB for the quarter ended September 30, 2004, our Annual Report on Form 10-KSB for the year ended December 31, 2003, our prospectus dated March 28, 2005 and our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: Corporate Investor Relations Bruce A. Kehr, M.D. Lev Janashvili Chief Executive Officer The Anne McBride Company InforMedix, Inc. Tel: 212-844-9290 T: 301-984-1566 E: ljan@annemcbride.com
InforMedix Holdings, Inc.
CONTACT: Corporate, Bruce A. Kehr, M.D., Chief Executive Officer ofInforMedix, Inc., +1-301-984-1566; or Investors, Lev Janashvili of The AnneMcBride Company, +1-212-844-9290, or ljan@annemcbride.com, for InforMedixHoldings, Inc.